Sfoglia per Autore
Carcinoma of pancreatic body and tail: any improvement in diagnosis and treatment modalities over the past decade?
2003-01-01 Falconi, Massimo; Mantovani, W.; Bettini, R.; Talamini, G.; Bassi, C.; Cascinu, S.; Oliani, C.; Pederzoli, P.
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
2006-01-01 D, Santini; F, Graziano; V, Catalano; M, DI SERI; E, Testa; Am, Baldelli; P, Giordani; A, LA CESA; B, Spalletta; B, Vincenzi; A, Russo; M, Caraglia; V, Virzi; Cascinu, S.; G, Tonini
New target therapies in advanced pancreatic cancer
2006-01-01 Cascinu, S; Verdecchia, L; Valeri, N; R., Berardi; Scartozzi, M
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients
2006-01-01 Scartozzi, M; Franciosi, V; Campanini, N; Benedetti, G; Barbieri, F; Rossi, Giorgio; Berardi, R; Camisa, R; Silva, Rr; Santineelli, A; Ardizzoni, A; Crino, L; Rindi, G; Cascinu, Stefano
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study
2006-01-01 Cazzaniga, Me; Dogliotti, L; Cascinu, Stefano; Barni, S; Labianca, R; Chiara, S; Conte, Pierfranco; Gasparini, G; Pasetto, L; Torri, V.
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy
2007-01-01 Scartozzi, M.; Bearzi, I.; Pierantoni, C.; Mandolesi, A.; Loupakis, F.; Zaniboni, A.; Catalano, V.; Quadri, A.; Zorzi, F.; Berardi, R.; Biscotti, T.; Labianca, R.; Falcone, A.; Cascinu, S.
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
2007-01-01 A, SARTORE-BIANCHI; M, Moroni; S, Veronese; C, Carnaghi; E, Bajetta; G, Luppi; A, Sobrero; C, Barone; Cascinu, S.; G, Colucci; E, Cortesi; M, Nichelatti; M, Gambacorta; S, Siena
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.
2007-01-01 Scartozzi, M.; Bearzi, I.; Berardi, R.; Mandolesi, A.; Pierantoni, C.; Cascinu, S.
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008-01-01 Van Cutsem, E.; Van de Velde, C.; Roth, A.; Lordick, F.; Kohne, C. -H.; Cascinu, S.; Aapro, M.
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II tria
2008-01-01 Cascinu, S; Berardi, R; Labianca, R; Siena, S; Falcone, A; Aitini, E; Barni, S; Di Costanzo, F; Dapretto, E; Tonini, G; Pierantoni, C; Artale, S; Rota, S; Floriani, I; Scartozzi, M; Zaniboni, A; Italian Group for the Study of Digestive Tract Cancer, (GISCAD)
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2
2009-01-01 Berardi, R.; Maccaroni, E.; Onofri, A.; Giampieri, R.; Pistelli, M.; Bittoni, A.; Scartozzi, M.; Pierantoni, C.; Mandolesi, A.; Bearzi, I.; Cascinu, S.
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
2009-01-01 Peeters, M; Siena, S; Van Cutsem, E; Sobrero, A; Hendlisz, A; Cascinu, S; Kalofonos, H; Devercelli, G; Wolf, M; Amado, Rg
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review
2009-01-01 Berardi, R.; Verdecchia, L.; Paolo, M. D.; Giampieri, R.; Scartozzi, M.; Pierantoni, C.; Bianconi, M.; Mazzanti, P.; Cascinu, S.
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis
2009-01-01 Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Pierantoni, C.; Loupakis, F.; Zaniboni, A.; Negri, F.; Quadri, A.; Zorzi, F.; Galizia, E.; Berardi, R.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, A.; Cascinu, S.
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan
2010-01-01 Scartozzi, M; Mandolesi, A; Giampieri, R; Pierantoni, C; Loupakis, F; Zaniboni, A; Galizia, E; Giustini, L; Rita, R; Bisonni, R; R., Berardi; Biagetti, S; Menzo, S; Falcone, A; Bearzi, I; Cascinu, S
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
2010-01-01 Cascinu, S; Galizia, E; Labianca, R; Ferraù, F; Pucci, F; Silva, Rr; Luppi, G; Beretta, Gd; Berardi, R; Scartozzi, M
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
2010-01-01 Scartozzi, M.; Mazzanti, P.; Giampieri, R.; Berardi, R.; Galizia, E.; Gasparini, S.; Zuccatosta, L.; Cascinu, S.
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
2010-01-01 Loupakis, F.; Masi, G.; Fornaro, L.; Vasile, E.; Allegrini, G.; Fontana, E.; Granetto, C.; Salvatore, L.; Mentuccia, L.; Andreuccetti, M.; Cortesi, E.; Merlano, M.; Cascinu, S.; Falcone, A.
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
2010-01-01 Scartozzi, M.; Bianconi, M.; Maccaroni, E.; Giampieri, R.; Berardi, R.; Cascinu, S.
Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
2010-01-01 Cascinu, S; Falconi, Massimo; Valentini, V; Jelic, S; ESMO Guidelines Working, Group
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Carcinoma of pancreatic body and tail: any improvement in diagnosis and treatment modalities over the past decade? | 1-gen-2003 | Falconi, Massimo; Mantovani, W.; Bettini, R.; Talamini, G.; Bassi, C.; Cascinu, S.; Oliani, C.; Pederzoli, P. | |
| Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial | 1-gen-2006 | D, Santini; F, Graziano; V, Catalano; M, DI SERI; E, Testa; Am, Baldelli; P, Giordani; A, LA CESA; B, Spalletta; B, Vincenzi; A, Russo; M, Caraglia; V, Virzi; Cascinu, S.; G, Tonini | |
| New target therapies in advanced pancreatic cancer | 1-gen-2006 | Cascinu, S; Verdecchia, L; Valeri, N; R., Berardi; Scartozzi, M | |
| Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients | 1-gen-2006 | Scartozzi, M; Franciosi, V; Campanini, N; Benedetti, G; Barbieri, F; Rossi, Giorgio; Berardi, R; Camisa, R; Silva, Rr; Santineelli, A; Ardizzoni, A; Crino, L; Rindi, G; Cascinu, Stefano | |
| Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study | 1-gen-2006 | Cazzaniga, Me; Dogliotti, L; Cascinu, Stefano; Barni, S; Labianca, R; Chiara, S; Conte, Pierfranco; Gasparini, G; Pasetto, L; Torri, V. | |
| Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy | 1-gen-2007 | Scartozzi, M.; Bearzi, I.; Pierantoni, C.; Mandolesi, A.; Loupakis, F.; Zaniboni, A.; Catalano, V.; Quadri, A.; Zorzi, F.; Berardi, R.; Biscotti, T.; Labianca, R.; Falcone, A.; Cascinu, S. | |
| Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab | 1-gen-2007 | A, SARTORE-BIANCHI; M, Moroni; S, Veronese; C, Carnaghi; E, Bajetta; G, Luppi; A, Sobrero; C, Barone; Cascinu, S.; G, Colucci; E, Cortesi; M, Nichelatti; M, Gambacorta; S, Siena | |
| Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. | 1-gen-2007 | Scartozzi, M.; Bearzi, I.; Berardi, R.; Mandolesi, A.; Pierantoni, C.; Cascinu, S. | |
| Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group | 1-gen-2008 | Van Cutsem, E.; Van de Velde, C.; Roth, A.; Lordick, F.; Kohne, C. -H.; Cascinu, S.; Aapro, M. | |
| Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II tria | 1-gen-2008 | Cascinu, S; Berardi, R; Labianca, R; Siena, S; Falcone, A; Aitini, E; Barni, S; Di Costanzo, F; Dapretto, E; Tonini, G; Pierantoni, C; Artale, S; Rota, S; Floriani, I; Scartozzi, M; Zaniboni, A; Italian Group for the Study of Digestive Tract Cancer, (GISCAD) | |
| Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2 | 1-gen-2009 | Berardi, R.; Maccaroni, E.; Onofri, A.; Giampieri, R.; Pistelli, M.; Bittoni, A.; Scartozzi, M.; Pierantoni, C.; Mandolesi, A.; Bearzi, I.; Cascinu, S. | |
| Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy | 1-gen-2009 | Peeters, M; Siena, S; Van Cutsem, E; Sobrero, A; Hendlisz, A; Cascinu, S; Kalofonos, H; Devercelli, G; Wolf, M; Amado, Rg | |
| Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review | 1-gen-2009 | Berardi, R.; Verdecchia, L.; Paolo, M. D.; Giampieri, R.; Scartozzi, M.; Pierantoni, C.; Bianconi, M.; Mazzanti, P.; Cascinu, S. | |
| Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis | 1-gen-2009 | Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Pierantoni, C.; Loupakis, F.; Zaniboni, A.; Negri, F.; Quadri, A.; Zorzi, F.; Galizia, E.; Berardi, R.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, A.; Cascinu, S. | |
| Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan | 1-gen-2010 | Scartozzi, M; Mandolesi, A; Giampieri, R; Pierantoni, C; Loupakis, F; Zaniboni, A; Galizia, E; Giustini, L; Rita, R; Bisonni, R; R., Berardi; Biagetti, S; Menzo, S; Falcone, A; Bearzi, I; Cascinu, S | |
| Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial | 1-gen-2010 | Cascinu, S; Galizia, E; Labianca, R; Ferraù, F; Pucci, F; Silva, Rr; Luppi, G; Beretta, Gd; Berardi, R; Scartozzi, M | |
| Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable? | 1-gen-2010 | Scartozzi, M.; Mazzanti, P.; Giampieri, R.; Berardi, R.; Galizia, E.; Gasparini, S.; Zuccatosta, L.; Cascinu, S. | |
| Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma | 1-gen-2010 | Loupakis, F.; Masi, G.; Fornaro, L.; Vasile, E.; Allegrini, G.; Fontana, E.; Granetto, C.; Salvatore, L.; Mentuccia, L.; Andreuccetti, M.; Cortesi, E.; Merlano, M.; Cascinu, S.; Falcone, A. | |
| Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer | 1-gen-2010 | Scartozzi, M.; Bianconi, M.; Maccaroni, E.; Giampieri, R.; Berardi, R.; Cascinu, S. | |
| Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up | 1-gen-2010 | Cascinu, S; Falconi, Massimo; Valentini, V; Jelic, S; ESMO Guidelines Working, Group |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile